Biodesix, Inc. recently announced new clinical findings showing that its novel investigational test, BDX008, based on profiling serum proteins, identifies patients with advanced melanoma who are more likely to have longer progression-free and overall survival with nivolumab therapy. Early data suggesting the test’s clinical potential for guiding anti-PD-1 therapy is being presented at the 30th annual meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, MD.
Investigational Blood Test Identifies Patients with Melanoma Who Are More Likely to Have Improved Survival on Nivolumab Therapy; Biodesix’ Blood Test is Independent of PD-L1 Expression
Chemotherapy drugs are typically successful at killing cancerous cells during initial treatment, but some cancers develop resistance to treatment. A new study by University of Wisconsin researchers has identified how this resistance develops in some breast cancers and should lead to more patient-specific treatments.
Scientists are now better able to predict how quickly the HIV virus will return after individuals stop treatment following a discovery by researchers at UNSW Australia and the University of Oxford.
Researchers working in the United States have demonstrated a technique that may enable real-time, in-flight detection of hypoxia in pilots.
A single blood test could reveal whether an otherwise healthy person is unusually likely to die of pneumonia or sepsis within the next 14 years. Based on an analysis of 10,000 individuals, researchers have identified a molecular byproduct of inflammation, called GlycA, which seems to predict premature death due to infections.